A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

Start Date15 Apr 2025

Sponsor / Collaborator

Resverlogix Corp.

NCT03160430

/ Not yet recruitingPhase 1/2

A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222

This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal Disease (ESRD) patients who receive hemodialysis as standard of care.
Part B of the study is a double-blind, placebo-controlled study in up to thirty six (36) ESRD patients receiving hemodialysis using a sequential cross-over design with RVX000222 at a daily oral dose of 100 mg b.i.d. (200 mg per day) or matching placebo in combination with SoC.
The primary objective of the study is to evaluate if treatment with RVX000222 in combination with standard of care (SoC) decreases plasma alkaline phosphatase in comparison to placebo and SoC.

Start Date22 Nov 2024

Sponsor / Collaborator

Resverlogix Corp.

NCT04915300

/ Unknown statusPhase 2IIT

Apabetalone for Pulmonary Arterial Hypertension: a Phase 2 Clinical Study

Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged. Short term placebo-controlled randomized trials assessing PAH-specific monotherapy with these molecules have reported improvements in pulmonary hemodynamics and exercise capacity. A recent meta-analysis also documented a reduction in short-term mortality of about ≈40% with such therapies. Several randomized clinical trials evaluating PAH-specific combination therapy have been conducted. Our recent meta-analysis showed that combination therapy was associated with a 35% risk reduction for the occurrence of clinical worsening compared to monotherapy. Nonetheless, the investigators also showed 17% of PAH patients receiving combination therapy still experienced clinical worsening over a median exposure of 16 weeks. Moreover, long-term survival on PAH-specific also therapy remains poor in the modern era, with a yearly mortality rate of 15 % in incident idiopathic PAH. The identification of innovative therapeutic targets and validation of these complementary therapeutic interventions are thus urgently needed in PAH.
The investigators and others (K. Stenmark, University of Colorado and H. Bogaard, VU University Medical Center, Amsterdam, personal communications), have published strong evidence that BRD4 plays a key role in the pathological phenotype in PAH accounting for disease progression and showed that BRD4 inhibition can reverse PAH in several animal models. Intriguingly, coronary artery disease (CAD) and metabolic syndrome are more prevalent in PAH compared with the global population, suggesting a link between these diseases. Interestingly, BRD4 is also a trigger for calcification and remodeling processes and regulates transcription of lipoprotein and inflammatory factors, all of which are important in PAH and CAD. Apabetalone, an orally available BRD4 inhibitor, is now in a clinical development stage with a good safety profile.
The overall objective of the study is to explore the efficacy and safety of apabetalone as an add-on therapy for adult PAH patients and to inform the conduct and the design of a Phase 3 trial.
The primary objective of the study is to assess the efficacy of apabetalone as evaluated by the change in PVR over a period of 24 weeks compared to placebo in adult subjects with PAH on stable background therapy.
Secondary objectives include changes at week 24 in 6MWD, plasma NT-proBNP concentration, WHO functional class, ESC/ERS risk stratification score, health-related quality of life and additional hemodynamic data from right heart.
Exploratory objectives are to evaluate the effects of apabetalone compared to placebo in adult subjects with PAH on mortality and clinically relevant morbidity events, and on circulating levels and transcription changes in whole blood markers of metabolism, vascular calcification, inflammation, DNA damage and leucocyte expression of BMPR2.

Start Date01 Oct 2023

Sponsor / Collaborator

Université Laval

[+2]

100 Clinical Results associated with Apabetalone

100 Translational Medicine associated with Apabetalone

100 Patents (Medical) associated with Apabetalone

119

Literatures (Medical) associated with Apabetalone

01 Oct 2026·GENE

Apabetalone mediates HIV-1 transcriptional activation and clearance of latently infected cells via LncRNA OSER1-AS1

Article

Author: Song, Bo ; Chen, Xiaohong ; Zhang, Lin ; Wang, Xue ; Cao, Lijun ; Liu, Siyu ; Lin, Xueru ; Fan, Guangfei ; Zhu, Liying

PURPOSE:

To explore the effect of Apabetalone on activating HIV-1 virus transcription and its molecular mechanism.

METHODS:

Peripheral blood mononuclear cells(PBMCs) latently infected with HIV-1 and J-Lat 10.6 cells were divided into two groups: a blank control group and an Apabetalone-treated group. After 48 h of culture with Apabetalone, bioinformatics and qRT-PCR were performed. Recombinant lentiviral vectors containing OSER1-AS1 and CDK9, along with empty vectors, were transfected into the cells for subsequent green fluorescent protein(GFP) fluorescence detection, cell cycle analysis, and apoptosis assays.

RESULTS:

Apabetalone efficiently activated HIV-1 viral transcription in J-Lat 10.6 and PBMC cells, increased the G₀/G₁ ratio of cells, and induced apoptosis. Apabetalone also downregulated the expression levels of MYC and p-Rb, and upregulated the expression levels of Tat and P21. Silencing OSER1-AS1 reduced apabetalone activation of HIV-1 transcription and inhibited apoptosis.

CONCLUSION:

Apabetalone enhances HIV-1 transcription by upregulating OSER1-AS1 expression, thereby promoting Tat-CDK9 binding.

01 Sep 2026·DIABETES RESEARCH AND CLINICAL PRACTICE

Metabolite sensing in cardiometabolic HFpEF: mechanisms and therapeutic perspectives

Review

Author: Wang, Xiaoming ; Zhang, Shujie ; Jiang, Weimin ; Ai, Sihan ; Zhu, Yao ; Fan, Yajie

Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is a prevalent subtype driven by obesity and diabetes. While systemic inflammation and myocardial fibrosis are known hallmarks, the mechanisms linking metabolic disturbances to cardiac remodeling remain poorly understood. Previous studies have often regarded metabolic abnormalities as passive byproducts of the disease process, neglecting the active regulatory role of metabolites themselves as bioactive signaling molecules. This review elucidates the molecular mechanisms of cardiometabolic HFpEF through the perspective of metabolite sensing. We elaborated on how different cell types decode changes in lipid metabolites, amino acids, TCA cycle intermediates, and gut microbiota-derived signals through specific sensors. These sensing cascades drive adipose tissue dysfunction, immunometabolic abnormalities, impaired myocardial metabolic flexibility, and fibrosis. Additionally, we focused on how intermediate metabolites directly serve as substrates for epigenetic and post-translational modifications, converting transient metabolic stress into a persistent pathological metabolic memory, and briefly discussed sex differences in metabolic sensing. Therapeutically, while SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone provide clinical benefits by restoring metabolic-cardiac homeostasis, targeting upstream metabolite-sensing pathways, such as epigenetic modifier regulators JQ1 and RVX-208 and gut microbiota metabolites, shows great potential. Ultimately, understanding how metabolites are sensed and translated into pathological signals is a key breakthrough for achieving precision therapy in cardiometabolic HFpEF.

01 Feb 2026·Advanced Science

Brd4 BD1 Domain Antagonism of MS436 Preserves Blood‐Brain Barrier Integrity via Rnf43/β‐Catenin Signaling Pathway

Article

Author: Yong Zhang ; Yushan Du ; Fen Ji ; Xiaochen Zhang ; Jingjing Zhang ; Chenxiao Li ; Jiangwei Xia ; Jianwei Jiao ; Shuang Liu ; Shukui Zhang ; Sihan Li

Abstract:

Blood‐brain barrier (BBB) disruption is central to neurodegenerative and cerebrovascular diseases, but its causal role and therapeutic targeting remain challenging. Bromodomain and extraterminal domain (BET) proteins, particularly Brd4, regulate transcription via dual bromodomains (BD1, BD2). While BD1 antagonists are explored for tumors and BD2 antagonists for inflammation, their impact on cerebrovascular integrity is unclear. Crucially, opposing BBB effects of domain‐specific BET antagonism: the BD2 antagonist RVX208 disrupt the BBB, whereas the BD1 antagonist MS436 significantly reduces leakage and improves neurological outcomes, revealing therapeutic potential is demonstrated. Mechanistically, endothelial Brd4 critically suppresses BBB stability. Its ablation upregulates tight junction (TJ) proteins. Brd4, acting exclusively through its BD1 domain, destabilizes TJs via Rnf43 is identified, which promotes β‐catenin and TJ protein degradation. This defines a novel Brd4 BD1/Rnf43/β‐catenin axis essential for BBB integrity. The findings establish Brd4 BD1 inhibition as a novel BBB‐protective strategy and position MS436 for repurposing in cerebrovascular diseases, necessitating reevaluation of domain‐specific BET targeting for neurovascular pathologies.

News (Medical) associated with Apabetalone

10 Sep 2026

·www.biospace.com

Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone’s Prevention of Heart Failure

Calgary, Alberta--(News - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone. "One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scientific Officer at Resverlogix. "These publications provide new insights into the biology that may underlie this benefit, suggesting that apabetalone reduces metabolic dysfunction and the formation of damaging scar tissue. Together, these findings strengthen our understanding of apabetalone's potential to protect the heart and improve outcomes for patients." Metabolic Shift Improves Liver and Heart Function The first article , titled: " Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice ", was published in the peer-reviewed journal Biomedicines and authored by a team of Resverlogix researchers including lead author Laura Tsujikawa. Key Highlights: Obesity is associated with metabolic dysfunction that affects multiple organs, contributing to fatty liver disease and heart failure Using a diet-induced obesity mouse model, researchers demonstrated a beneficial metabolic shift in apabetalone-treated mice, exemplified by an increase in circulating ketone levels This metabolic shift reduced lipid accumulation in the liver of treated mice and lowered levels of N-terminal pro-B-type natriuretic peptide ("NT-proBNP") – a diagnostic marker of heart failure These findings suggest that apabetalone may address underlying drivers of metabolic dysfunction, providing further support for its potential to reduce the burden of heart failure in patients, and introducing a rationale for its treatment of fatty liver disease Apabetalone Prevents Fibrosis Linked to Heart Failure The second article , titled: " BET Inhibitor Apabetalone Suppresses the Fibrotic Activation of Cardiac Fibroblasts Associated with Heart Dysfunction ", was published in the peer-reviewed journal Biomedicine & Pharmacotherapy , and written by lead authors Dr. Sylwia Wasiak and Dr. Dean Gilham. Key Highlights: Following cardiac injury, such as a heart attack, the body can produce too much extracellular matrix ("ECM") (the primary component of scar tissue), which can impair the heart's ability to stretch and contract Cardiac fibroblasts are a type of cells that specialize in regulating ECM deposition, and activate in response to cardiac injury Researchers found that treatment with apabetalone reduced the activation of cardiac fibroblasts and their deposition of ECM These findings suggest that apabetalone may help limit the formation of damaging scar tissue following cardiac injury, potentially helping patients preserve heart function, and align with observed reductions in heart failure hospitalizations About Apabetalone: Apabetalone (RVX-208) is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes. Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totaling over 4200 patient-years of safety data. Cardiology: Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed the ground-breaking findings from its Phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: linkedin.com/company/resverlogix-corp-/ Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 To view the source version of this press release, please visit

Phase 3Clinical ResultBreakthrough Therapy

26 Jun 2026

·www.biospace.com

Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders

Calgary, Alberta--(News - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes For Votes Withheld Percent For Percent Withheld Donald J. McCaffrey 152,172,240 4,026,590 97.42% 2.58% Kelly McNeill 152,453,272 3,745,558 97.60% 2.40% Siu Lun (Dicky) To 153,532,006 2,666,824 98.29% 1.71% Kenneth Zuerblis 153,419,286 2,779,544 98.22% 1.78% Bradley Glass 153,540,531 2,658,299 98.30% 1.70% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 15, 2026 (the "Information Circular"). The Information Circular is available on SEDAR+ at , and on the Resverlogix website at . A webcast archive of the executive presentation portion of the Meeting will be available HERE . About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: linkedin.com/company/resverlogix-corp-/ Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 To view the source version of this press release, please visit

19 May 2026

·www.resverlogix.com

Resverlogix Closes US$2 Million Shares-for-Interest Private Placement

THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES. CALGARY, Alberta, May 19, 2026, Resverlogix Corp. (“Resverlogix”) (TSX:RVX) announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the “Transaction”) with an arm’s length subscriber (the “Subscriber”). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057 (US$2,000,000). Shares acquired in the Transaction are subject to a four month hold period. After giving effect to the Transaction, the Subscriber holds approximately 7.8% of Resverlogix's common shares. The Transaction followed the settlement of CAD$2,760,057 (US$2,000,000) of accrued interest on indebtedness owing to the Subscriber by Zenith Capital Corp. (“Zenith”) by way of the assignment to the Subscriber of an equal amount of indebtedness owing by Resverlogix to Zenith. The Transaction is not related to the private placement announced by Resverlogix on February 18, 2026. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities to, or for the account or benefit of, persons in the United States or U.S. Persons. Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: linkedin.com/company/resverlogix-corp-/ This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts”, and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 www.resverlogix.com

100 Deals associated with Apabetalone

External Link

KEGG	Wiki	ATC	Drug Bank
D11131	Apabetalone	-	DB12000

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	Jordan	Resverlogix Corp.	15 Apr 2025
Post Acute COVID 19 Syndrome	Phase 3	Saudi Arabia	Resverlogix Corp.	15 Apr 2025
Post Acute COVID 19 Syndrome	Phase 3	United Arab Emirates	Resverlogix Corp.	15 Apr 2025
COVID-19	Phase 3	Canada	Resverlogix Corp.	14 Jan 2022
Angina, Unstable	Phase 3	Argentina	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Australia	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Belgium	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Bulgaria	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Croatia	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Germany	Resverlogix Corp.	01 Nov 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02586155 (BETonMACE, ERA2023)	Phase 3	Chronic Kidney Diseases	-	Apabetalone 100 mg	vsguoeynlt(pzuqqgavrh): HR = 0.5 (95% CI, 0.26 - 0.96), P-Value = 0.04	Positive	14 Jun 2023
				Placebo
NCT02586155 (BETonMACE, ASN2021)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	-	Apabetalone 1-25 µ M	acowebyhzw(lfondsfpsf) = tdmbuymlpd xcvgtwdvoj (byhakzuldo ) View more	Positive	27 Oct 2021
NCT03655704 (APPRoAcH-p, GlobeNewswire) Manual	Phase 1	Pulmonary Arterial Hypertension	7	Apabetalone	csoxtgcxrm(eamvttozzb) = improved iytwafpzbx (ggnyorhspi )	Positive	08 Sep 2021
NCT02586155 (BETonMACE, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	2,425	Atorvastatin+Rosuvastatin+Apabetalone (High-Intensity Statin Therapy+RVX000222)	uattsgyrui = lxmjaricdp pnpnltplxc (vydjjouiwj, swypndeqbb - gwhtumsdbm) View more	-	20 Aug 2021
				Placebo+Atorvastatin+Rosuvastatin (High-Intensity Statin Therapy+Placebo)	uattsgyrui = peffuqdhgd pnpnltplxc (vydjjouiwj, ducrjamzaf - auicfmgyiy) View more
NCT02586155 (BETonMACE, ERA2021)	Phase 3	Chronic Kidney Diseases	-	APABETALONE (TGF-β1)	noxbvglftt(erzeoryawi) = ythrxebwls jxdlkhgsii (qomxrjsngy ) View more	Positive	29 May 2021
				APABETALONE (LPS)	oykkcxmcga(kzixykvibl) = abwcvjrugi bdfthyxhmw (lftydxtlkv )
NCT02586155 (BETonMACE, ASN2020)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	2,425	Apabetalone	ywwzngdwth(swmhlxpsie) = pfqlahrbwj plywejbkat (jjmpmonuca, 1.67 - 3.44) View more	Positive	19 Oct 2020
				Placebo	ywwzngdwth(swmhlxpsie) = ozstqvetkw plywejbkat (jjmpmonuca, 1.67 - 3.44) View more
NCT02586155 (BETonMACE, ERA2020)	Phase 3	Diabetes Mellitus, Type 2 \| Acute Coronary Syndrome \| Chronic Kidney Diseases	2,425	Apabetalone (ABP)	jswpnvlniq(wauwennstm) = cbjahnwcmm htatwavnhc (cdzkoqnnpo )	Positive	06 Jun 2020
				Placebo (PBO)	jswpnvlniq(wauwennstm) = eomdjqjgsb htatwavnhc (cdzkoqnnpo )
NCT02586155 (BETonMACE, Pubmed \| J Coll Physicians Surg Pak \| JAMA) Manual	Phase 2	Diabetes Mellitus, Type 2 \| Acute Coronary Syndrome	2,425	Apabetalone	emvhghvgjl(dvnainmpuv) = yemijxpzxy rgfctiyrqa (luacieyqbt ) View more	Negative	28 Apr 2020
				Placebo	emvhghvgjl(dvnainmpuv) = nlcwqtfdor rgfctiyrqa (luacieyqbt ) View more
BETonMACE (ASN2019)	Phase 3	Acute Coronary Syndrome \| Diabetes Mellitus Alkaline Phosphatase	2,425	Apabetalone	hvnkzuoifq(jnkrijloai) = wkmgwcghsj irehwgdbna (dsqzealdvw )	Positive	05 Nov 2019
NCT02586155 (BETonMACE, Pubmed \| Am Heart J)	Phase 3	Acute Coronary Syndrome \| Diabetes Mellitus	2,425	Apabetalone 100 mg	qyjuvzxngi(qwuorjhpin) = xndyhwurab uwdnrnqjjz (pvdklidasw )	-	01 Nov 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis